Decoy Therapeutics to Execute 1-for-12 Reverse Stock Split

Written by Emily J. Thompson, Senior Investment Analyst

Source: seekingalpha

Updated: 1 hour ago

0mins

DCOY-8.68%

Should l Buy DCOY?

Source: seekingalpha

Reverse Stock Split Plan: Decoy Therapeutics will implement a 1-for-12 reverse stock split on March 6, 2026, aimed at reducing the number of outstanding shares to elevate the stock price and regain compliance with Nasdaq's minimum closing bid price requirement of $1.00.
Equity Change: Following the reverse split, the number of outstanding shares will decrease from approximately 6.38 million to around 532,000, which will significantly impact the company's market performance and investor confidence.
Trading Adjustment: Starting March 9, 2026, Decoy's common stock will trade on the Nasdaq Capital Market on a split-adjusted basis, affecting investor trading strategies and market liquidity.
Market Reaction: Following the reverse split announcement, DCOY shares fell 11.95% in premarket trading to $0.5785, indicating market concerns about the company's future performance and a cautious outlook on the split measures.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy DCOY?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on DCOY

About DCOY

Decoy Therapeutics Inc., formerly Salarius Pharmaceuticals, Inc., is a preclinical-stage biotechnology company that is leveraging machine learning and artificial intelligence (AI) tools alongside high-speed synthesis techniques to design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs. The Company’s initial pipeline is focused on respiratory viruses and GI cancers. In parallel, the Company is advancing discovery programs, including multi-virus decoy candidates designed to address overlapping respiratory threats, and cell-based and organoid-level validation of novel G protein-coupled receptor (GPCR)-targeted drug candidates outside of antivirals.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Decoy Therapeutics Announces 1-for-12 Reverse Stock Split

1 hour agoPRnewswire

Reverse Stock Split Plan: Decoy Therapeutics announced a 1-for-12 reverse stock split effective March 6, 2026, aimed at regaining compliance with Nasdaq's $1.00 minimum closing bid price requirement, ensuring the company's continued listing on the Nasdaq.
Shareholder Approval: At a special meeting on February 24, 2026, shareholders approved the board's proposal for the reverse split, which will reduce the number of outstanding shares from approximately 6.38 million to about 532,000, impacting all issued common stock uniformly.
Cash Compensation Mechanism: Following the reverse split, shareholders will receive cash in lieu of fractional shares based on the closing price on March 6, 2026, ensuring that shareholder rights are preserved despite the stock consolidation.
Future Financing Prospects: As a preclinical-stage biopharmaceutical company, Decoy Therapeutics is leveraging ML and AI tools to develop peptide conjugate therapeutics targeting serious unmet medical needs, and the reverse stock split is expected to enhance its market image and attract further investment.